Tobias Buchborn

Systems neuroscientist

Data updated

Papers

5 publications

Trials

0 clinical trials

Research Footprint

Tobias Buchborn appears in 5 tracked papers (2014–2026), most studied alongside Ibogaine, Psilocybin and LSD, across Depressive Disorders, Alcohol Use Disorder (AUD) and Substance Use Disorders (SUD).

Most-cited paper: Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing (152 citations).

Frequent co-authors: Robin Carhart-Harris, Christopher Timmermann and Leor Roseman.

Background & Research

Tobias Buchborn is a neuroscientist studying serotonergic hallucinogens and their effects across biological scales. According to his professional site, he earned a psychology degree and a PhD in neurobiology at Otto-von-Guericke University, then held a Marie Skłodowska-Curie Fellowship at Imperial College London before joining the Institute of Psychopharmacology at the Central Institute of Mental Health in Mannheim, University of Heidelberg. His research includes psychedelic tolerance, cortical and haemodynamic dynamics, psilocybin in alcohol-addiction models, and translational/conceptual work on altered states.